m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG00309)
Name |
Ro-4396686
|
||||
---|---|---|---|---|---|
Synonyms |
SCHEMBL5809947; CHEMBL606964
Click to Show/Hide
|
||||
Status |
Investigative
|
||||
Structure |
|
||||
Formula |
C24H24FN5O3
|
||||
InChI |
1S/C24H24FN5O3/c1-33-21-10-7-18(8-11-21)29-14-15-13-26-23(27-17-4-2-16(25)3-5-17)28-22(15)30(24(29)32)19-6-9-20(31)12-19/h2-5,7-8,10-11,13,19-20,31H,6,9,12,14H2,1H3,(H,26,27,28)/t19-,20-/m1/s1
|
||||
InChIKey |
KXEMINRANVTICS-WOJBJXKFSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Epidermal growth factor receptor (EGFR)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [1], [2] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [2], [3] | ||
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [2], [4] | ||
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [2], [5] | ||
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [2], [6] | ||
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [2], [7] | ||
Extracellular signal-regulated kinase 2 (ERK2)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro-4396686. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of Ro-4396686 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [8], [9] | ||
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro-4396686. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ro-4396686 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [9], [10] | ||
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of Ro-4396686 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [9], [10] | ||
Fibroblast growth factor receptor 4 (FGFR4)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Fibroblast growth factor receptor 4 (FGFR4) is a therapeutic target for Ro-4396686. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ro-4396686 through regulating the expression of Fibroblast growth factor receptor 4 (FGFR4). | [11], [12] | ||
Fyn tyrosine protein kinase (FYN)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Fyn tyrosine protein kinase (FYN) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Ro-4396686 through regulating the expression of Fyn tyrosine protein kinase (FYN). | [13], [14] | ||
Platelet-derived growth factor receptor alpha (PDGFRA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Ro-4396686. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-4396686 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [15], [16] | ||
Platelet-derived growth factor receptor beta (PDGFRB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Platelet-derived growth factor receptor beta (PDGFRB) is a therapeutic target for Ro-4396686. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Ro-4396686 through regulating the expression of Platelet-derived growth factor receptor beta (PDGFRB). | [16], [17] | ||
References